Scientific Opportunities and Public Needs Resource Allocation and Priority Setting at the NIH.

Slides:



Advertisements
Similar presentations
The NIH Roadmap for Medical Research
Advertisements

Research: Critical for Global Health Insert Your Name & the Date of the Presentation Here.
How to Build a Productive Relationship with NIH Topics Know your disease Know the NIH and NINDS Have realistic expectations Advocate for stronger NIH and.
San Diego EXPORT Center Improving Health Equity through Research, Training, Education, & Outreach C OUNCIL C OUNCIL C OMMUNITY C LINICS OF REHDI County.
Dr. John E. Niederhuber Director, National Cancer Institute Board of Scientific Advisors June 22, 2009 NCI Director’s Update.
National Institute on Aging Judith A. Salerno, M.D., M.S. Deputy Director NIA/NIH/DHHS ADC Meeting April 2004.
NIH at the Crossroads: Strategies for the Future Elias A. Zerhouni, M.D. Director National Institutes of Health.
1 Opportunity #4: Encouraging a greater focus on global health.
“It is the responsibility of those of us involved in today’s biomedical research enterprise to translate the remarkable scientific innovations we are witnessing.
Christine Lubinski Vice President for Global Health Infectious Diseases Society of America April 17, 2009 Germs Go Global Tuberculosis and HIV/TB Co-Infection.
1 Archived File The file below has been archived for historical reference purposes only. The content and links are no longer maintained and may be outdated.
U.S. Science Policy Cheryl L. Eavey, Program Director
Helena Chui, M.D. McCarron Professor and Chair of Neurology Director, Alzheimer Disease Research Center.
NIH at the Crossroads: Myths, Realities and Strategies for the Future Elias A. Zerhouni, M.D. Director, National Institutes of Health.
American Evaluation Association EVALUATION 2011 November 3, 2011 Approaches to Biomedical Research and Development Portfolio Analysis: Examples From the.
Faculty Senate December 1, Vision Statement for Creating a Statewide Network We are the premier, integrated comprehensive health system in.
Irish Health Research: Collaboration and Partnership HSE Regional Library & Information Health Research Seminar Dr. Steevens’ Hospital 11th February 2011.
National Institute on Aging Richard J. Hodes, M.D. Director,NIA/NIH/DHHS ADC Meeting – NIH Roadmap and Budget October 2003.
1 Inside the NIH 2009 NIH Overview of Program Funding and Grants Administration Sally Rockey, PhD Deputy Director, NIH Office of Extramural Research (OER)
The NIH Roadmap for Medical Research
Public Health and Healthcare in Ontario A Made in Ontario Solution for Public Health and Healthcare Andrew Papadopoulos Director, School of Occupational.
The Value of Partnerships in Fighting HIV/AIDS in Romania: Bringing Children New Hope Jeffrey L. Sturchio Vice President, External Affairs Europe, Middle.
Comparative Effectiveness Approaches with ARRA Funding and the Critical Role of Health IT Carolyn M. Clancy, MD Director Agency for Healthcare Research.
The American Recovery and Reinvestment Act: AHRQ's Role in Comparative Effectiveness Research Carolyn M. Clancy, MD, Director Jean Slutsky, Director, Center.
NIH Implementation of ARRA. NIH is grateful to President Obama and Congress for the opportunity for NIH to play its part in improving the Nation’s health.
Stakeholder Engagement and Transparency in The Effective Health Care Program Supriya Janakiraman MD MPH AHRQ.
American Heart Association Quality of Care and Outcomes Research Comparative Effectiveness Research Patrick Conway, MD, MSc Chief Medical Officer, Dept.
Science for Global Health: Fostering International Collaboration Norka Ruiz Bravo,PhD Special Advisor to the Director National Institutes of Health U.S.
NIAID Commitment to Influenza Research and Preparedness F. Gray Handley Associate Director for International Research Affairs National Institute of Allergy.
NCI Review of the Clinical Trials Process 6 th Annual National Forum on Biomedical Imaging in Oncology James H. Doroshow M.D. April 7, 2005 Bethesda, Maryland.
A National Approach to Cancer Control in Canada Remarks by Jeff Lozon, Chair Canadian Partnership Against Cancer.
NIH Roadmap and Chemoinformatics Jeffery Loo NLM Associate Fellow Welch Library Journal Club 2004/12/7.
Academic Health Center John Gillespie Nursing Medicine Allied Health Sciences Pharmacy.
1 Taking Bold Actions “Unity: Achieving Health Equity” June 22, 2012 Carlessia A. Hussein, RN, DrPH Director Office of Minority Health and Health Disparities.
The Review of Your NIH Grant Application Begins Here Richard Nakamura, Ph.D. Director NIH Center for Scientific Review.
The Sputnik Moment for U.S. Biomedical Research and NIH’s Formula for Success Sept. 22, 2015 – Senate Briefing Dr. Richard Nakamura, CSR Director Center.
The Role of Research in Osteopathic Medical Education American Association of Colleges of Osteopathic Medicine June 25, 2004 David B. Moore Associate Vice.
American Evaluation Association EVALUATION 2009 November 14, 2009 Building Data Systems to Support Evaluation in a Biomedical Research and Development.
ARRA and HHS Data Policy Initiatives Academy Health NAHDO All Payer All Claims Data Bases James Scanlon, HHS Deputy Assistant Secretary/ASPE.
The Future Research Agenda for Women’s Health Stacie E. Geller, Ph.D. Director, UIC Center for Research on Women and Gender and The National Center of.
NIH in the Post Doubling Era: Realities and Strategies for the Future Elias A. Zerhouni, M.D. Director National Institutes of Health.
INSTITUTIONS & U.S. Science and Technology Policy April 8, 2003 PAF591 - U.S. S&T Policy.
NIH ROADMAP FOR MEDICAL RESEARCH RESEARCH TEAMS OF THE FUTURE.
The Search for a “Better Way:” Reauthorization of the National Institutes of Health Elias A. Zerhouni, M.D., Director, NIH July 19, 2005 House Energy and.
National Center for Research Resources G. Iris Obrams, M.D., M.P.H., Ph.D. NCRR Update 5 August 2006.
The Importance of a Strategic Plan to Eliminate Health Disparities 2008 eHealth Conference June 9, 2008 Yvonne T. Maddox, PhD Deputy Director Eunice Kennedy.
Medicaid and the Effective Health Care Program William Lawrence, MD, MS Center for Outcomes and Evidence.
Institute of Health Science and Technology (IHST)
John Holcomb, MD, FACS UTHSC-Houston The National Problem  Lack of centralized, organized infrastructure to guide the direction of study and dispersal.
Robert H. Wiltrout Director, CCR Director’s Address.
Creating an Integrated Framework for Reducing Disparities in Health Care Quality Francis D. Chesley, Jr., MD Director Office of Extramural Research, Education.
Why Write A Grant? Elaine M. Hylek, MD, MPH Professor of Medicine Associate Director, Education and Training Division BU CTSI Section of General Internal.
Rationalizing the New Healthcare Paradigm Scientific Agenda vs. Patient Imperatives Scientific Agenda vs. Patient Imperatives.
CREATE-21 Slide 1 Creating Research, Extension, and Teaching Excellence for the 21st Century November 2006 Create-21.org.
Research Priorities & Trends for NIH in 2003 Claire T. Driscoll Director Technology Transfer Office National Human Genome Research Institute (NHGRI) Research.
Child Survival and Disease Programs Fund Accounts, Guidance, and Coding March 12, 2001.
ASTMH 2015 Capitol Hill Day Asks. ASTMH “Asks” Provide robust funding for NIH, CDC, USAID and DoD global health and infectious disease programs for fiscal.
1 Maximizing the Impact of Comparative Effectiveness Research: The Role of the DEcIDE Consortia Scott R. Smith, PhD AHRQ Center for Outcomes & Evidence.
Organizational Funding Portfolios and Beyond: Assessing the Full Research Landscape Panel Session 731 American Evaluation Association EVALUATION 2012 October.
HIV/AIDS The times they are a changing Roxana Rogers David Stanton Office of HIV/AIDS.
Science for Global Health: Fostering International Research Collaboration James Herrington, PhD, MPH Director Division of International Relations Fogarty.
NIH HIV/AIDS Research Priorities
National Association of Hispanic Nurses
The Medical Research Council
How does teamwork improve value. Dr Nils E
Centers for Disease Control (CDC) Tribal Advisory Committee Update and Public Health Initiatives Amy Groom, MPH National Center for Chronic Disease Prevention.
Chronic Disease Challenges & Opportunities for Improvement
Clinical and Translational Science Awards Program
Trial Funding and Engagement: The NIH Sponsored CTSA Program
National Institutes of Health
Presentation transcript:

Scientific Opportunities and Public Needs Resource Allocation and Priority Setting at the NIH

NIH  27 institutes and centers  Budget doubled in five years from FY1999 through FY2003  Majority of research is in life sciences  Receives more funding for R&D than any other non-defense agency  Does more basic research than any agency

NIH Budget in Millions of Dollars (FY ) $28,757,000 billion in FY2005 NIH budget doubled in five years from FY1999 through FY2003

NIH’s Criteria for Allocation of Research Funds  Highest scientific caliber  Best prospects for new knowledge (research programs vs specific diseases )  Diverse portfolio (cannot predict major discoveries)  Public health need as measured by disease burden  Necessary infrastructure for research

Constraints  Congress establishes separate appropriations accounts for each research institute and center $80.5 million for NIEHS Superfund research $150 million for Type 1 Diabetes (PL )  Commitment base (funding decisions made in previous years limit $ available for new initiatives)  Advances in science are not a commodity and cannot be purchased by simple expenditure of dollars

(Preference:)NIH Roadmap for Biomedical Research  New Pathways to Discovery, $137M Generating new knowledge and building a better toolbox for researchers  Multidisciplinary Research Teams of the Future, $39M Awards for centers and training, support for conferences  Re-engineering the Clinical Research Enterprise, $61M Facilitate rapid translation of discoveries from the lab to the clinic  Funds come from the NIH Director’s Discretionary Fund and the Institutes and Centers

(But:) Should Disease Prevalence Determine NIH $ Allocations?  YES Medical research fails to focus on diseases that cause the most suffering and death  $1,129/heart disease death  $723/stroke death  $4,995/diabetes death  $4,525/cancer death  $31,381/HIV,AIDS death* *Numbers are from 1998 data Diabetes kills more people than AIDS and breast cancer combined every year, yet in 2003 the NIH research allocation is $3,053 on each patient reported to have AIDS versus $70 on each diabetic. Plus, the NIH is only spending $145 on each patient with prostate disease, $164 on each patient with Alzheimer's Disease, $398 on Parkinson's Disease, even thought all these diseases kill many thousands more than AIDS each year.

Should Disease Prevalence Determine NIH $ Allocations?  NO Earmarking substitutes political decisions for scientific judgement Congress’ role is not micromanagement of disease research Distribution of funds is not an adequate measure of support for a specific disease (basic research is generally undirected) Explicit directives may slow research by keeping funds away from areas of greatest opportunity

NIH Priorities (FY 2005)  Recognizing the shift of disease burden, increased focus on chronic diseases e.g. cardiovascular disease, stroke, hypertension, cancer  Expanding initiative on obesity  Eliminating health disparities  Protecting against lethal bioterrorist acts through vaccines, diagnostics and therapeutics  Strong focus on infectious diseases SARS, West Nile Virus, influenza, malaria, TB, HIV/AIDS

Public Input at NIH  Advisory Committee to the Director  NIH Council of Public Representatives